Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $24.98 and last traded at $24.85, with a volume of 3700 shares traded. The stock had previously closed at $24.23.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Bank of America restated a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens restated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $32.29.
Check Out Our Latest Report on CPRX
Catalyst Pharmaceuticals Trading Down 0.1 %
The firm has a market capitalization of $3.12 billion, a PE ratio of 21.80, a PEG ratio of 3.31 and a beta of 0.84. The firm's fifty day moving average price is $22.53 and its 200 day moving average price is $21.72.
Insider Activity
In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $27,000. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals during the fourth quarter worth $29,000. Farther Finance Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period. Larson Financial Group LLC increased its stake in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. 79.22% of the stock is owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Read More
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
